#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12438	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2463	616.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1831	1831	T	818	T,G,C	813,4,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12438	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2463	616.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1565	1565	C	749	C,G	748,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	0	.	n	.	0	C902T	SNP	902	902	C	1517	1517	T	816	T,A,C	814,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1952	1952	A	834	A,C	832,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2586	2586	C	700	C,T,G	547,152,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	0	.	n	.	0	A2177G	SNP	2177	2177	A	2792	2792	G	660	G	660	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2660	2660	A	683	A,T	682,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3212	3212	C	738	C,A,T,G	734,1,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	21226	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4008	659.9	0	HET	.	.	.	C265T,G,A	.	265	265	C	880	880	C	859	C,T,G,A	625,231,1,1	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1856	folP	855	855	99.88	folP.l15.c17.ctg.1	2008	115.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1250	1252	AGC	188;189;190	A;G;C	188;189;190	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4450	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3996	139.0	1	SNP	p	S91F	0	.	.	271	273	TCC	877	879	TCC	185;182;182	T;C;C	185;182;182	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4450	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3996	139.0	1	SNP	p	D95G	0	.	.	283	285	GAC	889	891	GAC	185;185;185	G;A;C	185;185;185	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4450	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3996	139.0	1	SNP	p	D95N	0	.	.	283	285	GAC	889	891	GAC	185;185;185	G;A;C	185;185;185	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1796	mtrR	633	633	99.68	mtrR.l15.c30.ctg.1	1864	120.3	0	.	p	.	0	D79N	NONSYN	235	237	GAT	869	871	AAT	208;210;212	A;A;T	208;210;212	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1796	mtrR	633	633	99.68	mtrR.l15.c30.ctg.1	1864	120.3	1	SNP	p	G45D	0	.	.	133	135	GGC	767	769	GGC	203;200;200	G;G;C	202;200;200	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1074	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1530	87.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	0	.	p	.	0	T62M	NONSYN	184	186	ACG	770	772	ATG	175;173;174	A;T;G	175;173;174	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1736	1738	ATC	188;188;186	A;T;C	188;188;186	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1847	1849	GCC	196;193;193	G;C,T;C,G	196;191,2;192,1	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1889	1891	GCA	186;187;189	G;C;A	186;187;189	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	1	SNP	p	D86N	0	.	.	256	258	GAC	842	844	GAC	171;171;171	G;A;C	171;171;171	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	1	SNP	p	S87I	0	.	.	259	261	AGT	845	847	AGT	170;168;166	A;G;T	170;168;166	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	1	SNP	p	S87W	0	.	.	259	261	AGT	845	847	AGT	170;168;166	A;G;T	170;168;166	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	1	SNP	p	S87R	0	.	.	259	261	AGT	845	847	AGT	170;168;166	A;G;T	170;168;166	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4234	parC	2304	2304	99.61	parC.l15.c4.ctg.1	3496	151.1	1	SNP	p	S88P	0	.	.	262	264	TCC	848	850	TCC	168;169;166	T;C;C,T	168;169;165,1	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3888	parE	1986	1986	99.9	parE.l6.c4.ctg.1	3235	150.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1832	1834	GGC	227;231;229	G,A;G;C	226,1;231;229	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1487	1489	GCA	209;210;211	G;C;A,C	209;210;209,1	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1490	1492	ATC	209;210;210	A;T;C	208;210;210	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1502	1504	GTG	213;214;216	G,A;T;G	212,1;214;216	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1502	1504	GTG	213;214;216	G,A;T;G	212,1;214;216	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2006	2008	ACC	184;182;180	A;C;C	184;182;180	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2060	2062	GCG	197;197;196	G;C;G,A	197;197;195,1	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2060	2062	GCG	197;197;196	G;C;G,A	197;197;195,1	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2183	2185	GGC	210;207;208	G;G;C,T	210;207;207,1	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2192	2194	GGC	207;204;205	G;G;C	207;204;205	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3630	penA	1749	1749	99.89	penA.l15.c4.ctg.1	2999	151.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2210	2212	CCG	206;209;211	C;C;G	206;209;211	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4964	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3668	169.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1885	1887	CTG	209;211;210	C;T;G,C	209;211;209,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2074	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2360	109.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	641	643	GGC	145;142;143	G;G;C,T	145;142;141,2	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2074	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2360	109.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	823	823	C	153	C	153	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	Y39H	NONSYN	115	117	TAC	722	724	CAC	223;217;217	C;A;C	223;217;217	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	K88D	NONSYN	262	264	AAA	869	871	GAC	256;253;251	G,A;A,G;C,T	255,1;252,1;249,2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	E89T	NONSYN	265	267	GAA	872	874	ACA	251;251;250	A;C,T;A,G	251;250,1;249,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	H111R	NONSYN	331	333	CAT	938	940	CGT	209;209;206	C;G;T	209;209;206	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	D120G	NONSYN	358	360	GAC	965	967	GGC	187;183;183	G;G;C	187;183;183	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	L132S	NONSYN	394	396	TTG	1001	1003	TCG	172;172;172	T,G;C;G	171,1;172;172	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1313	1315	CGC	199;200;202	C;G;C	199;200;202	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	N237D	NONSYN	709	711	AAC	1316	1318	GAC	200;198;196	G;A,C;C,A	200;197,1;195,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	A251V	NONSYN	751	753	GCG	1358	1360	GTG	191;190;191	G;T;G	191;190;191	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	N277H	NONSYN	829	831	AAC	1436	1438	CAC	209;212;211	C;A;C	209;212;211	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	R307K	NONSYN	919	921	AGA	1526	1528	AAA	216;216;215	A;A,G;A	215;214,1;214	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	2432	porB1a	984	984	98.58	porB1a.l6.c17.ctg.1	2016	150.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	1538	1540	GCA	212;213;212	G,A;C;A	211,1;213;212	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	8780	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5488	199.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2348	2350	CAT	241;241;244	C;A;T	241;241;244	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1266	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1557	101.5	1	SNP	p	V57M	1	.	.	169	171	ATG	774	776	ATG	217;219;221	A;T;G	217;219;221	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	10850	tetM	1920	1920	100.0	tetM.l15.c4.ctg.1	3253	416.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
